Literature DB >> 21537080

Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload.

Norimichi Koitabashi1, Thomas Danner, Ari L Zaiman, Yigal M Pinto, Janelle Rowell, Joseph Mankowski, Dou Zhang, Taishi Nakamura, Eiki Takimoto, David A Kass.   

Abstract

The cardiac pathological response to sustained pressure overload involves myocyte hypertrophy and dysfunction along with interstitial changes such as fibrosis and reduced capillary density. These changes are orchestrated by mechanical forces and factors secreted between cells. One such secreted factor is TGF-β, which is generated by and interacts with multiple cell types. Here we have shown that TGF-β suppression in cardiomyocytes was required to protect against maladaptive remodeling and involved noncanonical (non-Smad-related) signaling. Mouse hearts subjected to pressure overload and treated with a TGF-β-neutralizing Ab had suppressed Smad activation in the interstitium but not in myocytes, and noncanonical (TGF-β-activated kinase 1 [TAK1]) activation remained. Although fibrosis was greatly reduced, chamber dysfunction and dilation persisted. Induced myocyte knockdown of TGF-β type 2 receptor (TβR2) blocked all maladaptive responses, inhibiting myocyte and interstitial Smad and TAK1. Myocyte knockdown of TβR1 suppressed myocyte but not interstitial Smad, nor TAK1, modestly reducing fibrosis without improving chamber function or hypertrophy. Only TβR2 knockdown preserved capillary density after pressure overload, enhancing BMP7, a regulator of the endothelial-mesenchymal transition. BMP7 enhancement also was coupled to TAK1 suppression. Thus, myocyte targeting is required to modulate TGF-β in hearts subjected to pressure overload, with noncanonical pathways predominantly affecting the maladaptive hypertrophy/dysfunction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21537080      PMCID: PMC3104748          DOI: 10.1172/JCI44824

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  50 in total

1.  Targeted disruption of Smad4 in cardiomyocytes results in cardiac hypertrophy and heart failure.

Authors:  Jian Wang; Ning Xu; Xinheng Feng; Ning Hou; JiShuai Zhang; Xuan Cheng; Yeguang Chen; Youyi Zhang; Xiao Yang
Journal:  Circ Res       Date:  2005-09-08       Impact factor: 17.367

2.  TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II.

Authors:  Jo El J Schultz; Sandra A Witt; Betty J Glascock; Michelle L Nieman; Peter J Reiser; Stacey L Nix; Thomas R Kimball; Thomas Doetschman
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

3.  The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy.

Authors:  P Liao; D Georgakopoulos; A Kovacs; M Zheng; D Lerner; H Pu; J Saffitz; K Chien; R P Xiao; D A Kass; Y Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

Review 4.  The TGF beta superfamily in myocardium: ligands, receptors, transduction, and function.

Authors:  T Brand; M D Schneider
Journal:  J Mol Cell Cardiol       Date:  1995-01       Impact factor: 5.000

5.  TGF-beta1 induces cardiac hypertrophic responses via PKC-dependent ATF-2 activation.

Authors:  Joong-Yeon Lim; Sung Joon Park; Ha-Young Hwang; Eun Jung Park; Jae Hwan Nam; Joon Kim; Sang Ick Park
Journal:  J Mol Cell Cardiol       Date:  2005-10       Impact factor: 5.000

6.  Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms.

Authors:  Stefan Hein; Eyal Arnon; Sawa Kostin; Markus Schönburg; Albrecht Elsässer; Victoria Polyakova; Erwin P Bauer; Wolf-Peter Klövekorn; Jutta Schaper
Journal:  Circulation       Date:  2003-02-25       Impact factor: 29.690

Review 7.  Ubiquitin-mediated activation of TAK1 and IKK.

Authors:  A Adhikari; M Xu; Z J Chen
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

8.  Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats.

Authors:  Fumitaka Kuwahara; Hisashi Kai; Keisuke Tokuda; Mamiko Kai; Akira Takeshita; Kensuke Egashira; Tsutomu Imaizumi
Journal:  Circulation       Date:  2002-07-02       Impact factor: 29.690

9.  Endothelial-to-mesenchymal transition contributes to cardiac fibrosis.

Authors:  Elisabeth M Zeisberg; Oleg Tarnavski; Michael Zeisberg; Adam L Dorfman; Julie R McMullen; Erika Gustafsson; Anil Chandraker; Xueli Yuan; William T Pu; Anita B Roberts; Eric G Neilson; Mohamed H Sayegh; Seigo Izumo; Raghu Kalluri
Journal:  Nat Med       Date:  2007-07-29       Impact factor: 53.440

10.  Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models.

Authors:  Norimichi Koitabashi; Djahida Bedja; Ari L Zaiman; Yigal M Pinto; Manling Zhang; Kathleen L Gabrielson; Eiki Takimoto; David A Kass
Journal:  Circ Res       Date:  2009-06-11       Impact factor: 17.367

View more
  158 in total

1.  Pharmacological inhibition of TGFβ receptor improves Nkx2.5 cardiomyoblast-mediated regeneration.

Authors:  Wen-Pin Chen; Yuan-Hung Liu; Yi-Jin Ho; Sean M Wu
Journal:  Cardiovasc Res       Date:  2014-10-31       Impact factor: 10.787

Review 2.  Reverse remodeling in heart failure--mechanisms and therapeutic opportunities.

Authors:  Norimichi Koitabashi; David A Kass
Journal:  Nat Rev Cardiol       Date:  2011-12-06       Impact factor: 32.419

3.  Endothelial expression of hypoxia-inducible factor 1 protects the murine heart and aorta from pressure overload by suppression of TGF-β signaling.

Authors:  Hong Wei; Djahida Bedja; Norimichi Koitabashi; Dongmei Xing; Jasper Chen; Karen Fox-Talbot; Rosanne Rouf; Shaoping Chen; Charles Steenbergen; John W Harmon; Harry C Dietz; Kathleen L Gabrielson; David A Kass; Gregg L Semenza
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-08       Impact factor: 11.205

4.  Bleomycin induces endothelial mesenchymal transition through activation of mTOR pathway: a possible mechanism contributing to the sclerotherapy of venous malformations.

Authors:  Wei Zhang; Gang Chen; Jian-Gang Ren; Yi-Fang Zhao
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

5.  Genetic Analysis of Connective Tissue Growth Factor as an Effector of Transforming Growth Factor β Signaling and Cardiac Remodeling.

Authors:  Federica Accornero; Jop H van Berlo; Robert N Correll; John W Elrod; Michelle A Sargent; Allen York; Joseph E Rabinowitz; Andrew Leask; Jeffery D Molkentin
Journal:  Mol Cell Biol       Date:  2015-04-13       Impact factor: 4.272

6.  GDF11 Decreases Pressure Overload-Induced Hypertrophy, but Can Cause Severe Cachexia and Premature Death.

Authors:  Shavonn C Harper; Jaslyn Johnson; Giulia Borghetti; Huaqing Zhao; Tao Wang; Markus Wallner; Hajime Kubo; Eric A Feldsott; Yijun Yang; Yunichel Joo; Xinji Gou; Abdel Karim Sabri; Priyanka Gupta; Maria Myzithras; Ashraf Khalil; Michael Franti; Steven R Houser
Journal:  Circ Res       Date:  2018-11-09       Impact factor: 17.367

Review 7.  Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies.

Authors:  Kavita Sharma; David A Kass
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

8.  A clinical commentary on the articles "strategies for tissue engineering cardiac constructs to affect functional repair following myocardial infarction" and "stem cell-based cardiac tissue engineering" : repairing, reprogramming, and renewing: the promise of myocardial cytotherapeutics.

Authors:  Navin K Kapur
Journal:  J Cardiovasc Transl Res       Date:  2011-08-11       Impact factor: 4.132

Review 9.  Fibroblasts and the extracellular matrix in right ventricular disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Cardiovasc Res       Date:  2017-10-01       Impact factor: 10.787

10.  BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure.

Authors:  Qiming Duan; Sarah McMahon; Priti Anand; Hirsh Shah; Sean Thomas; Hazel T Salunga; Yu Huang; Rongli Zhang; Aarathi Sahadevan; Madeleine E Lemieux; Jonathan D Brown; Deepak Srivastava; James E Bradner; Timothy A McKinsey; Saptarsi M Haldar
Journal:  Sci Transl Med       Date:  2017-05-17       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.